cytogenetic approaches to cancer. One such approach, fluorescence in situ hybridization (FISH), he said, enables scientists to assess the number of copies of specific genes in individual cells by staining them with fluorescently labeled DNA probes. They can then map the distribution of specific abnormalities within a tumor. In some cases, FISH reveals an "amazing amount of heterogeneity" in the number of copies in solid tumors, Gray noted.
The technique is ideal for studying genes already known to be involved in cancer, but most investigators suspect that a lot more genes are out there, perhaps even more important than those that are now known.
Improving FISH
In the search for novel genes, the technique of comparative genomic hybridization (CGH), an outgrowth of FISH that was developed a few years ago to scrutinize the entire tumor genome for variations from normal cells, has come in handy. In the procedure, a tumor's DNA labeled with a green fluorescent dye becomes one probe, and normal DNA labeled with a red fluorescent dye becomes a second. The two probes are mixed together and hybridized to "target" normal chromosomes. Differences in the number of copies between the tumor and normal genomes are reflected in the ratio of green to red probe fragments that bind to various locations on the chromosomes.
Thus, any region of the tumor genome that has lost some copies of its genes will have a lower green to red ratio than average. The procedure has pointed investigators to regions in the genome that are potential targets for discovery of genes and development of diagnostics and therapeutics. Now researchers have developed a high-resolution extension of CGH. At the American Society of Human Genetics meeting in San Francisco, Dan Pinkel, Ph.D., who works with Gray at UCSF, Donna Albertson, Ph.D., of Lawrence Berkeley National Laboratory, and Gray reported on the use of high density arrays of cloned DNA on glass microscope slides to replace the use of metaphase chromosomes in CGH.
"The new technique is much more quantitative than conventional CGH and can be done using any tumor tissue for which pure genomic DNA is available," Pinkel said. "We expect that the high-resolution analysis will assist with identification of new cancer genes."
"Known Suspects"
Alternatively, an array that would contain all the "known suspects," such as p53 or erb-B2, would allow more specific tailoring of therapy. "The amount of work needed to establish that is immense," said Pinkel. "This technique is one way to help."
Another method of assessing gene amplification or deletion has been de-
Genetic Therapy for Breast Cancer Reaches the Drawing Board
As an example of possible therapies targeted to specific genetic defects, Chris Benz, M.D., professor of medicine at the University of California, San Francisco, and colleagues have carried out animal studies to eradicate the gene erb-B2's protein product using a specific immunoliposome, a fat molecule attached to an antibody and a chemotherapy drug. The protein is a cell surface receptor for a growth factor. Dennis Slamon, M.D., and his team at the University of California, Los Angeles, discovered in 1987 that erb-B2 is amplified in some 20% of breast cancers. Such patients are now known to have a poorer prognosis than some other breast cancer patients.
Benz and co-workers created an immunoliposome by hooking a portion of an anti-erb-B2 monoclonal antibody made by Genentech to a liposome containing doxorubicin. Then they studied the immunoliposome in breast cancer cell lines that overexpress the erb-B2 product and in nude mice carrying human breast cancers.
In all cases the immunoliposome was engulfed by the tumor cells, and better tumor response was achieved than with the drug, liposome, or monoclonal antibody alone. With this "proof of concept," further studies, including clinical trials, are on the drawing board, said Benz.
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